Investors
Oncopeptides strives to ensure that analysts, investors, shareholders and financial media are provided with correct information to enhance understanding of our operations.
Information for investors
Oncopeptides recently decided to carry out a fully guaranteed new share issue of approximately SEK 150 million with preferential rights for the company’s existing ordinary shareholders.
Investor news
See our latest Investor presentations, webcast, transcripts and interviews.
Press release - October 16, 2025
Journal of Cancer Research and Clinical Oncology: Exceptional long-term responses to Pepaxti
Read press release
Investor Relations Contact
David Augustsson
Director of Corporate Affairs
ir@oncopeptides.com
+46 762 29 38 68
Please note that David will be on partial parental leave during the fall of 2025 with intermittent access to phone/e-mail. For the quickest response, please use the e-mail above which is monitored at all times during business hours.
The share
Oncopeptides is listed on Nasdaq Stockholm Small Cap under the trade symbol ONCO, since February 22, 2017.
Financial reports
See all of our financial reports together with related documents and webcasts.
Upcoming events
2025-10-06 - 2025-11-04
Silent period
Other
2025-11-05
Interim Report Q3 202
Report
2026-01-19 - 2026-02-18
Silent period
Other